Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
102786-61-8
Molecular formula
Not available
Molecular weight
50000 g/mol
Drug class
Recombinant activated human coagulation factor VIIa (rFVIIabypassing haemostatic agent)
Mechanism of action
Activated factor VII binds tissue factor and activates factor X and, on activated platelet surfaces, factor IX; this supports local thrombin generation and fibrin formation even when factor VIII or IX activity is inhibited or deficient.
Indications / reported uses
Treatment of bleeding episodes and prevention of bleeding during surgery or invasive procedures in defined patients with congenital haemophilia and factor VIII/IX inhibitors, acquired haemophilia, congenital factor VII deficiency or Glanzmann thrombasthenia with platelet-transfusion refractoriness; exact eligibility is product-specific
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Eptacog Alfa Environmental Risk Assessment (ERA) (the Eptacog Alfa ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.